Prophylactic antibiotics for cystic fibrosis

Area of Science:

• Medical research
• Pediatric pulmonology
• Infectious disease management

Background:

• Continuous prophylactic antibiotic use is common in cystic fibrosis (CF) patients, particularly infants, to prevent Staphylococcus aureus infections and lung damage.
• This approach aims to mitigate early pulmonary complications and preserve lung health in individuals with CF.
• The review evaluates the efficacy and potential risks associated with prophylactic antibiotic therapy in CF management.

Purpose of the Study:

• To compare continuous oral antibiotic prophylaxis with standard care (as-needed antibiotic courses) in cystic fibrosis patients.
• To assess the impact of prophylaxis on respiratory tract pathogens, need for additional antibiotics, lung function, and survival.
• To evaluate the adverse effects associated with continuous prophylactic antibiotic use.

Main Methods:

• A systematic review of randomized or pseudo-randomized trials comparing continuous oral prophylactic antibiotics (≥1 year) with intermittent therapy.
• Searches included the Cochrane Cystic Fibrosis and Genetic Disorders Group trials register, databases, journals, and conference abstracts.
• Data extraction and quality assessment were performed by two independent reviewers, focusing on lung function, nutrition, survival, pathogen isolates, and adverse reactions.

Main Results:

• Two studies with 66 patients (mostly infants) were included. Prophylaxis reduced Staphylococcus aureus prevalence and the need for additional oral antibiotics, leading to fewer hospital admissions in the first two years of life.
• No significant effect on other common pathogens or infant lung function after one year of treatment was observed.
• Data on adverse effects and long-term outcomes, such as Pseudomonas aeruginosa acquisition and survival beyond two years, were not available.

Conclusions:

• Early initiation of anti-staphylococcal antibiotic prophylaxis in infancy, continued up to two years, may offer benefits in managing Staphylococcus aureus infections in cystic fibrosis.
• Insufficient evidence exists to support the use of prophylaxis in older children or adults, or for durations exceeding two years.
• Further research is needed to determine the long-term efficacy and safety of prophylactic antibiotic strategies in cystic fibrosis patients of all age groups.